Basic schematic showing how the [email protected]/I of the present study can function as a PA imaging-guided RA therapeutic. PBNPs: Prussian blue nanoparticles; CIA: collagen-induced arthritis; PL: pulsed laser; PA: photoacoustic; ROS: reactive oxygen species; RA: rheumatoid arthritis.
(Image by SIAT)
The high level of reactive oxygen species (ROS) in the rheumatoid arthritis (RA) microenvironment and its persistent inflammatory nature can promote damage to joints, bones, and the synovium. Strategies that integrate effective RA microenvironment regulation with imaging-based monitoring could lead to improvements in the diagnosis and treatment of RA.
A joint research team from the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences and the University of Texas at Austin has proposed a new strategy that can achieve targeted treatment of rheumatoid arthritis.
The researchers integrated small interfering RNAs (siRNAsT/I) and Prussian blue nanoparticles (PBNPs) to silence the expression of the proinflammatory cytokines TNF-?/IL-6 and scavenge the ROS associated with the RA microenvironment.
The study was published in PNAS on Oct. 18.
To enhance the in vitro and in vivo biological stability, biocompatibility, and targeting capability of the siRNAsT/I and PBNPs, the researchers prepared macrophage membrane vesicles (MMVs) to construct biomimetic nanoparticles, [email protected]T/I.
They found that the [email protected]T/I suppressed TNF-?/IL-6 expression and overcame the hypoxic nature of the RA microenvironment, thus alleviating RA-induced joint damage in a mouse model.
Moreover, near-infrared photoacoustic imaging (PAI) allowed the targeting behavior of the [email protected]T/I to be followed in real time, thus permitting an evaluation of their therapeutic efficacy without the need for invasive procedures.
These findings show that macrophage-biomimetic [email protected]T/I and their analogues assisted by PAI can provide a new strategy for RA diagnosis, treatment, and monitoring.
Original Article: New Strategy Enables Targeted Treatment of Rheumatoid Arthritis
The Latest on: Rheumatoid arthritis treatment
- Trial assesses the impact of two immunomodulators in reducing CV risk among rheumatoid arthritis patientson December 5, 2022 at 3:48 pm
People with rheumatoid arthritis are at increased risk of cardiovascular (CV) disease, with studies indicating an approximate 50 percent increase in risk of CV events such as heart attack and stroke.
- Trial compares therapies for reducing cardiovascular risk among people with rheumatoid arthritison December 5, 2022 at 1:09 pm
People with rheumatoid arthritis are at increased risk of cardiovascular (CV ... two different immunomodulator treatment strategies produced similar reductions in CV risk." More information: Daniel H ...
- How awareness, early diagnosis can reduce arthritis prevalence in Nigeriaon December 5, 2022 at 4:57 am
As the burden of arthritis prevalence continues to rise in Africa’s most populous nation, healthcare professionals have called for the management of the ...
- Rheumatoid Arthritis Treatment Market 2023 Is Flourishing Around the World by 2026on December 4, 2022 at 9:49 pm
Rheumatoid Arthritis Treatment market revenue was Million USD in 2016, grew to Million USD in 2020, and will reach Million USD in 2026, with a CAGR of % during review period.” Ask for Sample Report ...
- Immune-regulating nanoparticles prevent arthritis in susceptible miceon December 4, 2022 at 7:38 pm
Autoimmune diseases are a common health problem, and while system-wide immune suppression can help relieve symptoms, this can cause other complications. In a new study, scientists at Scripps Research ...
- Subclinical Rheumatoid Arthritis: To Treat or Not to Treat?on December 2, 2022 at 4:00 pm
Does a positive ACPA test mean a person will develop rheumatoid arthritis? Should they be treated early – even without symptoms?
- Cardiovascular Risk Marker Improved With Common Rheumatoid Arthritis Drugson December 2, 2022 at 10:02 am
Patients in the trial had active rheumatoid arthritis despite methotrexate treatment, suggesting they were experiencing "a high degree of systemic inflammation" that would diminish with any clinically ...
- Rheumatoid Arthritis Treatment Market: Technological Improvements Piloting Growth During 2022-2028| New 90 No. Pages Reporton December 2, 2022 at 2:41 am
Rheumatoid Arthritis Treatment Market | Outlook 2023-2028 | Pre and Post-COVID Research is Covered, Report Information ...
- New Views on Difficult-to-Treat Rheumatoid Arthritison December 1, 2022 at 1:00 am
About 20% of people with rheumatoid arthritis fit the description of having “difficult to treat” or refractory disease, according to experts. As more is known about this subgroup of patients, ...
- What Does It Feel Like When You Have Rheumatoid Arthritis In Your Neck?on November 27, 2022 at 2:48 pm
People who have rheumatoid arthritis may experience symptoms that set it apart from other types of arthritis. This is how it feels to have it in the neck.
via Bing News
The Latest on: Rheumatoid arthritis treatment
[google_news title=”” keyword=”rheumatoid arthritis treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News